Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Medlive Technology Co's PEG is 1. Medlive Technology Co's 5-Year TTM EBITDA Growth Rate is 25.
Medlive Technology Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.49. Therefore, the Peter Lynch Fair Value for today is HK$12.13.
The historical rank and industry rank for Medlive Technology Co's Peter Lynch Fair Value or its related term are showing as below:
HKSE:02192'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58 Med: 0.9 Max: 0.94
Current: 0.58
During the past 8 years, the highest Price to Peter Lynch Fair Value Ratio of Medlive Technology Co was 0.94. The lowest was 0.58. And the median was 0.90.
HKSE:02192's Price-to-Peter-Lynch-Fair-Value is ranked better than 86.59% of 164
companies
in the Healthcare Providers & Services industry
Industry Median: 1.36
vs HKSE:02192: 0.58
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Medlive Technology Co (HKSE:02192) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Medlive Technology Co's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
6.975
/
12.13
=
0.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co Peter Lynch Fair Value Related Terms
Medlive Technology Co Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co Peter Lynch Fair Value Chart
HKSE:02192 vs VEEV, BTSG, TEM: Peter Lynch Fair Value Comparison
For the Health Information Services subindustry, Medlive Technology Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co Price-to-Peter-Lynch-Fair-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medlive Technology Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of HK$12.13 mean?
Medlive Technology Co (HKSE:02192) has a Peter Lynch Fair Value of HK$12.13 as of Sep. 07, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Medlive Technology Co and its competitors. According to the industry distribution chart, Medlive Technology Co ranks #22 out of 164 companies in the Healthcare Providers & Services industry, placing it in the top 13.4%.
Is Medlive Technology Co's Peter Lynch Fair Value too high?
Medlive Technology Co's current Peter Lynch Fair Value is HK$12.13. Based on the distribution chart, Medlive Technology Co ranks #22 out of 164 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medlive Technology Co has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's Peter Lynch Fair Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #22 out of 164 companies for Peter Lynch Fair Value. This places Medlive Technology Co in the top 13% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Healthcare Providers & Services company?
The median Peter Lynch Fair Value among Healthcare Providers & Services companies is 1.36, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Peter Lynch Fair Value is 1.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current Peter Lynch Fair Value is HK$12.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Medlive Technology Co (HKSE:02192) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$14.74, compared to a current price of HK$6.98 — trading 52.7% below its estimated fair value. The current Peter Lynch Fair Value is HK$12.13. Medlive Technology Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Medlive Technology Co (HKSE:02192), the current Peter Lynch Fair Value is HK$12.13 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (HKSE:02192) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of HK$6.98 is trading 52.7% below its estimated GF Value™ of HK$14.74.
GuruFocus considers Medlive Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02192:
Peter Lynch Fair Value: HK$12.13
GF Value™: HK$14.74 vs. price of HK$6.98 (52.7% below fair value)
No single metric tells the full story. See the HKSE:02192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
92GF Score
Get the complete analysis for HKSE:02192
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02192 has been successfully added to your 
